Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.
Canadian contract manufacturing and testing firm Garmen Laboratories will be acquired by Cancer drug developer Advanomics Corp in a deal announced today.
UK drugmaker, GlaxoSmithKline and Moscow-based JSC Binnopharm have formed a deal that will see the latter produce GSK’s cervical cancer, rotavirus and pneumococcal vaccines in Russia.
Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Global vaccine revenues will be $52bn (€36.2bn) in 2016, more than double the total for 2009, driven by new products and indication expansions of established therapies, according to a report.
Merck & Co has earmarked nearly $1bn in investment funding to boost its quality and manufacturing capacity in vaccines, said chief executive Dick Clark on the firm’s fourth-quarter results call.
Electroporation specialist Inovio Biomedical Corp and vaccine
developer VGX Pharmaceuticals believe that their recently announced
merger will create a firm capable of rapidly moving DNA vaccine
candidates from the laboratory to the...
Continued weakness in the market for products used in the
manufacture of biologic drugs was the main reason why Millipore
experienced a 'challenging' quarter, according to CEO Martin
Madaus.
A recent report suggests that the market for paediatric and
adolescent vaccines is set to grow four-fold over the next decade,
spearheaded by Wyeth's Prevnar as the first blockbuster vaccine.
NanoImaging Services has opened what it claims is a first of its
kind fee-for-service imaging business to enable structural
characterisation and validation of biological drugs throughout the
development pipeline.
The race is on between cervical cancer vaccines Gardasil and
Cervarix as they begin to battle it out to win a more than £100m a
year supply contract with the UK Department of Health.
GlaxoSmithKline is seeking prequalification status from the World
Health Organisation for its new cervical cancer vaccine, Cervarix,
in a bid to speed up its availability to developing countries.
GlaxoSmithKline (GSK) has been granted EU approval of its
adjuvanted cervical cancer vaccine Cervarix, and is confident that
the jab can challenge the likes of Merck's high-profile Gardasil.
GlaxoSmithKline's cervical cancer vaccine, Cervarix, has received a
positive opinion from the European Commission for Human Medicinal
Products (CHMP), bringing a competitor to Merck & Co's dominant
Gardasil vaccine a...
LabTechnologist.com brings you its periodic round up of industry
news, with Qiagen agreeing to buy Digene, Roche Diagnostics
settling a tax evasion investigation and agreements between Bio-Rad
and Beckman Coulter, Waters and Rosetta...
US drug regulators have requested more proof that Dendreon's
prostate cancer treatment works before they will approve it,
sending the Seattle-based biotech's shares plummeting.
An exclusive license to a late stage product has enabled
Sanofi-aventis to up the stakes in a bid to be the first company to
release a dedicated cancer vaccine.
The US Congress has asked the country's National Institute of
Environmental Health Sciences (NIEHS) to conduct research on the
connection between vaccines containing mercury and neurological
disorders, further battering public...
GlaxoSmithKline (GSK) publishes its fourth quarter earnings, which
indicate a significant profit rise well ahead of industry
predictions, with momentum building in its product pipeline of new
drugs giving the company the go-ahead...
Britiain's largest drugsmaker, GlaxoSmithKline, announced it is to
expand its ability to increase vaccines supplies by acquiring a
vaccine research and production facility from rivals Wyeth.
A technique that boosts the laboratory production of human
papillomavirus by 1,000 times compared to existing methods could
accelerate research into new treatments for HPV infection, which
causes genital warts and cervical cancer,...
GlaxoSmithKline has announced plans to acquire the Corixa
Corporation, which represents an important strategic deal for GSK's
vaccines division, GSK Bio. The division is the only major vaccine
maker with active R&D programs...
The prospect of a simple vaccination to prevent cervical cancer
took a major step with the publication of positive Phase II trial
results on a candidate from Merck, called Gardasil, in the April
edition of the medical journal The...
